|[August 27, 2014]
Enanta Pharmaceuticals to Present at Three Upcoming Investor Conferences
WATERTOWN, Mass. --(Business Wire)--
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and
development-focused biotechnology company dedicated to creating small
molecule drugs in the infectious disease field, today announced that Jay
R. Luly, Ph.D., President and Chief Executive Officer, and other members
of Enanta management will participate in the following three investor
conferences during the month of September:
Wednesday, September 3, 2014, the FBR & Company Inaugural Healthcare
Conference in Boston. There is no webcast presentation.
Thursday, September 4, 2014, at 2:00 p.m. ET, Enanta management will
present a corporate overview during the Baird 2014 Healthcare
Conference in New York.
Monday, September 8, 2014 at 2:00 p.m. ET, Enanta management will
present a corporate overview during the Morgan Stanley 2014 Global
Halthcare Conference in New York.
Live webcasts and replays of the Baird 2014 Healthcare conference and
the Morgan Stanley 2014 Global Healthcare conference presentations can
be accessed by visiting the "Calendar of Events" section on the
"Investors" page of Enanta's website at www.enanta.com.
A replay of each webcast will be available following the presentation
and will be archived for approximately 30 days.
Enanta Pharmaceuticals is a research and development-focused
biotechnology company that uses its robust chemistry-driven approach and
drug discovery capabilities to create small molecule drugs in the
infectious disease field. Enanta is discovering, and in some cases
developing, novel inhibitors designed for use against the hepatitis C
virus (HCV). These inhibitors include members of the direct acting
antiviral (DAA) inhibitor classes - protease (partnered with AbbVie),
NS5A (partnered with Novartis) and nucleotide polymerase - as well as a
host-targeted antiviral (HTA) inhibitor class targeted against
cyclophilin. Additionally, Enanta has created a new class of
antibiotics, called Bicyclolides, for the treatment of multi-drug
resistant bacteria, with a focus on developing an intravenous and oral
treatment for hospital and community MRSA (methicillin-resistant Staphylococcus
[ InfoTech Spotlight's Homepage ]